chr12-54293362-T-C
Position:
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_001136023.3(NFE2):āc.134A>Gā(p.Glu45Gly) variant causes a missense change. The variant allele was found at a frequency of 0.0001 in 1,526,510 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.000039 ( 0 hom., cov: 32)
Exomes š: 0.00011 ( 2 hom. )
Consequence
NFE2
NM_001136023.3 missense
NM_001136023.3 missense
Scores
8
11
Clinical Significance
Conservation
PhyloP100: 4.12
Genes affected
NFE2 (HGNC:7780): (nuclear factor, erythroid 2) Enables several functions, including WW domain binding activity; identical protein binding activity; and protein N-terminus binding activity. Contributes to cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to act upstream of or within several processes, including labyrinthine layer blood vessel development; negative regulation of bone mineralization; and negative regulation of syncytium formation by plasma membrane fusion. Part of protein-DNA complex. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -8 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.035786986).
BS2
High AC in GnomAd4 at 6 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
NFE2 | NM_001136023.3 | c.134A>G | p.Glu45Gly | missense_variant | 3/3 | ENST00000435572.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
NFE2 | ENST00000435572.7 | c.134A>G | p.Glu45Gly | missense_variant | 3/3 | 1 | NM_001136023.3 | P1 | |
ENST00000553061.1 | n.545+16187T>C | intron_variant, non_coding_transcript_variant | 5 |
Frequencies
GnomAD3 genomes AF: 0.0000395 AC: 6AN: 151950Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
6
AN:
151950
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000218 AC: 44AN: 202134Hom.: 0 AF XY: 0.000269 AC XY: 29AN XY: 107762
GnomAD3 exomes
AF:
AC:
44
AN:
202134
Hom.:
AF XY:
AC XY:
29
AN XY:
107762
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000107 AC: 147AN: 1374442Hom.: 2 Cov.: 31 AF XY: 0.000136 AC XY: 92AN XY: 675362
GnomAD4 exome
AF:
AC:
147
AN:
1374442
Hom.:
Cov.:
31
AF XY:
AC XY:
92
AN XY:
675362
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000395 AC: 6AN: 152068Hom.: 0 Cov.: 32 AF XY: 0.0000673 AC XY: 5AN XY: 74332
GnomAD4 genome
AF:
AC:
6
AN:
152068
Hom.:
Cov.:
32
AF XY:
AC XY:
5
AN XY:
74332
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
25
Asia WGS
AF:
AC:
2
AN:
3478
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 18, 2023 | The c.134A>G (p.E45G) alteration is located in exon 3 (coding exon 2) of the NFE2 gene. This alteration results from a A to G substitution at nucleotide position 134, causing the glutamic acid (E) at amino acid position 45 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D;D;D;D;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
.;.;.;T;T
M_CAP
Benign
T
MetaRNN
Benign
T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
L;L;L;L;.
MutationTaster
Benign
D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;N;N;D
REVEL
Benign
Sift
Uncertain
D;D;D;D;D
Sift4G
Benign
T;T;T;T;.
Polyphen
D;D;D;D;.
Vest4
MutPred
Gain of catalytic residue at E45 (P = 6e-04);Gain of catalytic residue at E45 (P = 6e-04);Gain of catalytic residue at E45 (P = 6e-04);Gain of catalytic residue at E45 (P = 6e-04);Gain of catalytic residue at E45 (P = 6e-04);
MVP
MPC
1.5
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at